Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD
Time: 1:15 pm
day: Conference Day Two
Details:
- Translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges
- Leveraging established conjugation chemistry expertise while adapting linker design for degrader-specific payloads
- Developing novel preclinical assays to evaluate non-cytotoxic mechanisms of action and predict clinical efficacy
